Trimethoprim-sulfamethoxazole-induced hypersensitivity syndrome associated with reactivation of human herpesvirus-6.

A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (TMP)-sulfamethoxazole (SMX) treatment. After the withdrawal of TMP-SMX and the administration of high-dose steroid, these systemic symptoms gradually resolved. During the disease course, the patient showed a transient increase in anti-human herpesvirus (HHV)-6 antibody titers and HHV-6 DNA in the peripheral blood, indicating the reactivation of a latent HHV-6 infection. This is the first case of TMP-SMX-induced hypersensitivity syndrome associated with the reactivation of a latent viral infection.

[1]  Y. Kuwano,et al.  Drug-Induced Hypersensitivity Syndrome Associated with Transient Hypogammaglobulinaemia and Increase in Serum IgE Level , 2005, Dermatology.

[2]  S. Burastero,et al.  Viral Replication-Independent Blockade of Dendritic Cell Maturation and Interleukin-12 Production by Human Herpesvirus 6 , 2005, Journal of Virology.

[3]  Y. Seino,et al.  A case of fulminant Type 1 diabetes associated with mexiletine hypersensitivity syndrome , 2004, Diabetic medicine : a journal of the British Diabetic Association.

[4]  C. Finch,et al.  Anticonvulsant Hypersensitivity Syndrome: Treatment with Corticosteroids and Intravenous Immunoglobulin , 2004, Southern medical journal.

[5]  T. Shiohara,et al.  Association between anticonvulsant hypersensitivity syndrome and human herpesvirus 6 reactivation and hypogammaglobulinemia. , 2004, Archives of dermatology.

[6]  L. Dagna,et al.  Selective suppression of IL-12 production by human herpesvirus 6. , 2003, Blood.

[7]  Y. Yamakawa,et al.  Carbamazepine‐induced hypersensitivity syndrome associated with transient hypogammaglobulinaemia and reactivation of human herpesvirus 6 infection demonstrated by real‐time quantitative polymerase chain reaction , 2003, The British journal of dermatology.

[8]  S. Taş,et al.  Management of Drug Rash with Eosinophilia and Systemic Symptoms (DRESS Syndrome): An Update , 2003, Dermatology.

[9]  F. Rozenberg,et al.  Drug‐induced hypersensitivity syndrome associated with Epstein–Barr virus infection , 2003, The British journal of dermatology.

[10]  V. Descamps,et al.  Prodynorphin gene promoter polymorphism and temporal lobe epilepsy , 2003, Annals of neurology.

[11]  Y. Kunisaki,et al.  Salazosulfapyridine induced hypersensitivity syndrome associated with reactivation of humanherpes virus 6. , 2003, Internal medicine.

[12]  E. Chiappini,et al.  Evidence for a T-Lymphocyte Dependent Mechanism Involving Proinflammatory Cytokines in Anticonvulsant Hypersensitivity Syndrome: A Case Report , 2002, International journal of immunopathology and pharmacology.

[13]  M. Comar,et al.  HHV‐6 infects human aortic and heart microvascular endothelial cells, increasing their ability to secrete proinflammatory chemokines , 2002, Journal of medical virology.

[14]  T. Yoshikawa,et al.  Latent infection of human herpesvirus 6 in astrocytoma cell line and alteration of cytokine synthesis , 2002, Journal of medical virology.

[15]  D. Taub,et al.  Gene Expression Profile of Herpesvirus-Infected T Cells Obtained Using Immunomicroarrays: Induction of Proinflammatory Mechanisms , 2001, Journal of Virology.

[16]  T. Nagatani,et al.  Anticonvulsant hypersensitivity syndrome associated with reactivation of cytomegalovirus , 2001, The British journal of dermatology.

[17]  N. Sekine,et al.  Rapid loss of insulin secretion in a patient with fulminant type 1 diabetes mellitus and carbamazepine hypersensitivity syndrome. , 2001, JAMA.

[18]  J. Roujeau,et al.  Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? , 2000, Archives of dermatology.

[19]  M. Tohyama,et al.  Severe hypersensitivity syndrome due to sulfasalazine associated with reactivation of human herpesvirus 6. , 1998, Archives of dermatology.

[20]  R. Inagi,et al.  Human herpesvirus 6 infection as a risk factor for the development of severe drug-induced hypersensitivity syndrome. , 1998, Archives of dermatology.

[21]  C. Barrios,et al.  Phenytoin hypersensitivity syndrome with positive patch test. A possible cross-reactivity with amitriptyline. , 1998, Journal of investigational allergology & clinical immunology.

[22]  D. Descamps,et al.  Human herpesvirus 6 infection associated with anticonvulsant hypersensitivity syndrome and reactive haemophagocytic syndrome , 1997, The British journal of dermatology.

[23]  X. Yang,et al.  Interferon‐gamma (IFN‐γ) regulates production of IL‐10 and IL‐12 in human herpesvirus‐6 (HHV‐6)‐infected monocyte/macrophage lineage , 1997, Clinical and experimental immunology.

[24]  D. Di Luca,et al.  Role of IFN gamma on TNF alpha, IL-1 beta and IL-6 release during HHV-6 infection. , 1996, The new microbiologica.

[25]  L. Hughes-Davies,et al.  Severe adverse cutaneous reactions to drugs. , 1995, The New England journal of medicine.

[26]  E. C. Schirmer,et al.  T-cell activation is required for efficient replication of human herpesvirus 6 , 1990, Journal of virology.

[27]  Z. Ikezawa,et al.  Human herpesvirus infection in drug-induced hypersensitivity syndrome, toxic epidermal necrolysis and Stevens-Johnson syndrome , 2004 .

[28]  S. Card,et al.  Trimethoprim-sulfamethoxazole-associated hepatotoxicity - part of a hypersensitivity syndrome. , 2003, The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique.

[29]  S. Ashkenazi,et al.  Successful treatment of antiepileptic drug hypersensitivity syndrome with intravenous immune globulin. , 2001, Pediatrics.